Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
Breast Cancer
DRUG: Pyrotinib|DRUG: Etoposide
Objective Response Rate(ORR), Refers to the proportion of patients whose tumors have shrunk to a certain proportion and maintained for a certain period of time, including cases of CR and PR, RECIST 1.1 were used to assess objective tumor remission, 4 months
Progression Free Survival(PFS), the date from the first dose to the first occurrence of disease progression or death from any cause, whichever occurs first, 4 months|disease control rate(DCR), Percentage of confirmed complete remission (CR), partial remission (PR), and disease stable (SD) cases in patients with evaluable efficacy, 4 months
The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer